Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from CSL ( (AU:CSL) ).
CSL Limited reported a weaker first half for the period ended 31 December 2025, with total revenue slipping 2% year-on-year to US$8.33 billion and reported net profit after tax plunging 80% to US$401 million. Underlying NPATA, which strips out amortisation of acquired IP and significant one-off items, declined a more modest 6% to US$1.95 billion, reflecting underlying business pressures despite continued profitability.
On a constant-currency basis, revenue fell 4% and NPAT dropped 81%, underscoring the extent of the earnings deterioration when currency effects are removed. Earnings per share mirrored the headline profit decline, with basic EPS down 80%, while underlying NPATA per share fell 6%, and the board maintained an unfranked interim dividend of US$1.30 per share, signaling an ongoing commitment to shareholder returns despite the sharp profit contraction.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$198.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is an Australia-based global biotechnology company focused on developing and manufacturing biopharmaceutical products, including plasma-derived and recombinant therapies, vaccines and specialty medicines. The company serves patients worldwide with a strong presence in major healthcare markets and is listed on the Australian Securities Exchange under the ticker CSL.
Average Trading Volume: 920,389
Technical Sentiment Signal: Sell
Current Market Cap: A$87.57B
For a thorough assessment of CSL stock, go to TipRanks’ Stock Analysis page.